All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10462224" target="_blank" >RIV/00064203:_____/23:10462224 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/23:10462224

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1200/JCO.22.01760" target="_blank" >10.1200/JCO.22.01760</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial

  • Original language description

    PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m(2) every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS +- SE) and overall survival (OS +- SE) rates were 75.2% +- 0.6% and 82.6% +- 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% +- 1.4% and 94.7% +- 1.1%; IR (n = 4,111), 77.9% +- 0.7% and 85.7% +- 0.6%; and HR (n = 1,452), 60.8% +- 1.5% and 68.4% +- 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% +- 1.2% and 72.8% +- 1.2%, respectively (P = .55), while those in patients receiving MTX doses of 2 g/m(2) (n = 1,056) and MTX 5 g/m(2) (n = 1,027) were 78.8% +- 1.4% and 78.9% +- 1.4%, respectively (P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m(2) was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Clinical Oncology

  • ISSN

    0732-183X

  • e-ISSN

    1527-7755

  • Volume of the periodical

    41

  • Issue of the periodical within the volume

    19

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    13

  • Pages from-to

    3499-3511

  • UT code for WoS article

    001037224100009

  • EID of the result in the Scopus database

    2-s2.0-85161436569